Table 1.
Summary of all vaccine-based clinical trials discussed in this review.
| Clinical Trial Number | Target antigen | Platform | Vehicle | Adjuvant | Reference |
|---|---|---|---|---|---|
| NCT02287428 | Personalized neoantigen | Peptide | Poly-ICLC | (24) | |
| NCT02149225 | Personalized neoantigen | Peptide | Poly-ICLCGM-CSF | (23) | |
| NCT02287428 | Personalized neoantigen | Peptide | Pembrolizumab | (25) | |
| NCT03422094 | Personalized neoantigen | Peptide | Poly-ICLC Nivolumab Ipilimumab | (26) | |
| NCT01480479 | EGFRvIII | Peptide | Keyhole limpet hemocyanin GM-CSF | ||
| NCT01498328 | EGFRvIII | Peptide | Bevacizumab | (33) | |
| NCT03299309 | pp65 CMV | Peptide | Tetanus-diphtheria toxoid Montanide ISA 51 | (35) | |
| NCT04280848 | TERT | Peptide | Montanide ISA 51 | (38) | |
| NCT02454634 | IDH1 R132H | Peptide | Montanide Imiquimod | (41, 43) | |
| NCT02193347 | IDH1 R132H | Peptide | Tetanus-diphtheria toxoid | (42) | |
| NCT02455557 | Survivin | Peptide | Keyhole limpet hemocyanin Montanide ISA 51 GM-CSF | (45) | |
| WT1 | Peptide | Montanide ISA 51 | (48) | ||
| NCT02498665 | WT1 DSP-7888 | Peptide | (50) | ||
| NCT02750891 | WT1 DSP-7888 | Peptide | (51) | ||
| NCT03149003 | WT1 DSP-7888 | Peptide | Bevacizumab | (52) | |
| NCT01130077 | Survivin IL-13 receptor alpha 2 EphA2 | Peptide | Poly-ICLC | (54) | |
| NCT01222221 | IMA950 | Peptide | GM-CSF | (55) | |
| NCT01920191 | IMA950 | Peptide | Poly-ICLC | (56) | |
| NCT03665545 | IMA950 | Peptide | Poly-ICLC Pembrolizumab | (57) | |
| NCT03491683 | WT1 PSMA TERT | DNA | IL-12 Cemiplimab | (62–64) | |
| NCT04015700 | Personalized neoantigen | DNA | IL-12 | (65) | |
| NCT04573140 | Tumor mRNA pp65 CMV | RNA | (68) | ||
| EGFRvIII | Peptide | DCs | Keyhole limpet hemocyanin | (72) | |
| WT1 Tumor lysate | Peptide | DCs | OK-432 | (73) | |
| NCT02649582 | WT1 | RNA | DCs | (74) | |
| NCT02049489 | CD133 | Peptide | DCs | (75) | |
| IL-13 receptor alpha 2 | Peptide | DCs | (76) | ||
| NCT00639639 | pp65 CMV | RNA | DCs | GM-CSF | (77) |
| NCT00639639 | pp65 CMV | RNA | DCs | Tetanus-diphtheria toxoid CCL3 | (78) |
| NCT02465268 | pp65 CMV | RNA | DCs | GM-CSF Tetanus-diphtheria toxoid | (80) |
| NCT02529072 | pp65 CMV | RNA | DCs | Nivolumab | (81) |
| NCT01280552 | ICT-107 | Peptide | DCs | (82) | |
| NCT02546102 | ICT-107 | Peptide | DCs | (31) | |
| NCT00045968 | Tumor lysate | Peptide | DCs | (83) | |
| 2009-015979-27 (EudraCT) | Tumor lysate | Peptide | DCs | (84) | |
| 2006-002881-20 (EudraCT) | Tumor lysate | Peptide | DCs | (85) | |
| NCT00323115 | Tumor lysate | Peptide | DCs | (86) | |
| NCT01006044 | Tumor lysate | Peptide | DCs | (87) | |
| 2008-005035-15 (EudraCT) | Tumor lysate | Peptide | DCs | (88) | |
| Tumor lysate | Peptide | DCs | (89) | ||
| NCT01808820 | Tumor lysate | Peptide | DCs | Imiquimod | (31) |
| NCT03879512 | Tumor lysate | Peptide | DCs | Cyclophosphamide Nivolumab Ipilimumab | (31) |
| NCT04201873 | Tumor lysate | Peptide | DCs | Pembrolizumab Poly-ICLC | (31) |
| NCT00846456 | Glioma stem cells | RNA | DCs | (90) | |
| NCT01567202 | Glioma stem cells | Peptide | DCs | ||
| NCT02010606 | Glioma stem cells | Peptide | DCs | ||
| NCT02820584 | Glioma stem cells | Peptide | DCs | ||
| NCT00293423 | Tumor lysate | Peptide | HSPs | (102) | |
| NCT03018288 | Tumor lysate | Peptide | HSPs | Pembrolizumab | (103) |
| NCT02366728 | pp65 CMV | RNA | DCs | Tetanus-diphtheria toxoid Basiliximab | (106) |
| NCT03927222 | pp65 CMV | RNA | DCs | GM-CSF Tetanus-diphtheria toxoid | (107) |
| NCT01204684 | Tumor lysate | Peptide | DCs | Imiquimod/Resiquimod Poly-ICLC | (108) |
| NCT03688178 | pp65 CMV | RNA | DCs | Varlilumab Tetanus-diphtheria | (117) |